8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 29, 2026·SEC
Material company update
Feb 27, 2026·SEC
Disc Medicine, Inc.(IRON)Earnings, Financials & Key Ratios
IRON•NASDAQ
$67.53
$2.58B mkt cap·Price updated May 7, 2026
AboutDisc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.Show more
- Revenue$0
- EBITDA-$236M-81.9%
- Net Income-$212M-94.0%
- EPS (Diluted)-6.01-51.8%
- ROE-35.86%-29.3%
- ROIC-38%+47.7%
- Debt/Equity0.00-96.3%
- Interest Coverage-57.73+69.5%
IRON Key Insights
Disc Medicine, Inc. (IRON) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 39.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 27.9% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IRON Price & Volume
Disc Medicine, Inc. (IRON) stock price & volume — 10-year historical chart
Loading chart...
IRON Growth Metrics
Disc Medicine, Inc. (IRON) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-94.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-50.63%
Return on Capital
10 Years-48.09%
5 Years-48.09%
3 Years-34.79%
Last Year-37.95%
IRON Recent Earnings
Disc Medicine, Inc. (IRON) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026EPS
$1.65
Est $1.62
-1.7%
Revenue
—
Est $437,500
Q1 2026
Feb 26, 2026EPS
$1.62
Est $1.69
+4.1%
Revenue
—
Est $150,000
Q4 2025
Nov 6, 2025EPS
$1.77
Est $1.48
-19.6%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$1.58
Est $1.17
-35.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.65vs $1.62-1.7% | —vs $437,500 |
| Q1 2026 | Feb 26, 2026 | $1.62vs $1.69+4.1% | —vs $150,000 |
| Q4 2025 | Nov 6, 2025 | $1.77vs $1.48-19.6% | — |
| Q3 2025 | Aug 7, 2025 | $1.58vs $1.17-35.0% | — |
Based on last 12 quarters of dataView full earnings history →
IRON Peer Comparison
Disc Medicine, Inc. (IRON) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 RYTM | 6.59B | 96.23 | -30.94 | 45.83% | -93.84% | -204.35% | 1.77 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RVMD | 30.3B | 142.51 | -23.95 | -83.22% | 0.10 | |||
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 | |
 PTCT | 5.35B | 64.49 | 8.29 | 114.51% | -22.58% |
Compare IRON vs Peers
Disc Medicine, Inc. (IRON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IRON Income Statement
Disc Medicine, Inc. (IRON) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 322K | 0 | 0 | 0 | 0 | 281K |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -322K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -281K▲ 0% |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | - | - | - | - |
| Operating Expenses | 33.72M | 30.93M | 47.48M | 91.13M | 129.72M | 235.74M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 5.87M | 5.76M | 14.04M | 21.86M | 33.05M | 65.38M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 28.17M | 25.17M | 33.44M | 69.26M | 96.67M | 170.64M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | -322K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -34.04M▲ 0% | -30.93M▲ 9.1% | -47.48M▼ 53.5% | -91.13M▼ 91.9% | -129.72M▼ 42.4% | -236.02M▼ 81.9% |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | 9.13% | -53.48% | -91.94% | -42.35% | -81.95% |
| EBITDA | -33.72M | -30.9M | -47.39M | -91.03M | -129.56M | -235.74M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | 8.35% | -53.35% | -92.09% | -42.34% | -81.95% |
| D&A (Non-Cash Add-back) | 322K | 32K | 89K | 100K | 156K | 281K |
| EBIT | -34.01M | -30.93M | -47.48M | -76.33M | -108.43M | -208.22M |
| Net Interest Income | -6.79M | -2.14M | 709K | 14.8M | 20.72M | 24.15M |
| Interest Income | 37K | 14K | 709K | 14.8M | 21.29M | 27.76M |
| Interest Expense | 6.83M | 2.16M | 0 | 0 | 572K | 3.61M |
| Other Income/Expense | -6.8M | -5.04M | 648K | 14.79M | 20.72M | 24.2M |
| Pretax Income | -40.84M▲ 0% | -35.97M▲ 11.9% | -46.83M▼ 30.2% | -76.33M▼ 63.0% | -109M▼ 42.8% | -211.82M▼ 94.3% |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 99K | 355K | 361K |
| Effective Tax Rate % | 0% | 0% | 0% | -0.13% | -0.33% | -0.17% |
| Net Income | -40.84M▲ 0% | -35.97M▲ 11.9% | -46.83M▼ 30.2% | -76.43M▼ 63.2% | -109.36M▼ 43.1% | -212.18M▼ 94.0% |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | 11.92% | -30.19% | -63.22% | -43.08% | -94.03% |
| Net Income (Continuing) | -40.84M | -35.97M | -46.83M | -76.43M | -109.36M | -212.18M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -27.02▲ 0% | -44.88▼ 66.1% | -45.05▼ 0.4% | -3.42▲ 92.4% | -3.96▼ 15.8% | -6.01▼ 51.8% |
| EPS Growth % | - | -66.1% | -0.38% | 92.41% | -15.79% | -51.77% |
| EPS (Basic) | -27.02 | -44.88 | -45.05 | -3.42 | -3.96 | -6.01 |
| Diluted Shares Outstanding | 1.51M | 801.47K | 1.04M | 22.32M | 27.61M | 35.3M |
| Basic Shares Outstanding | 1.51M | 801.47K | 1.04M | 22.32M | 27.61M | 35.3M |
| Dividend Payout Ratio | - | - | - | - | - | - |
IRON Balance Sheet
Disc Medicine, Inc. (IRON) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Total Current Assets | 5.07M | 90.48M | 198.49M | 365.66M | 493.62M | 803.9M |
| Cash & Short-Term Investments | 4.5M | 88.04M | 194.61M | 360.38M | 489.88M | 791.15M |
| Cash Only | 4.5M | 88.04M | 194.61M | 360.38M | 192.43M | 91.14M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 297.45M | 700.01M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | -802K | 0 | 0 | 3.73M | 12.75M |
| Total Non-Current Assets | 3.25M | 1.93M | 1.71M | 2.33M | 3.16M | 2.98M |
| Property, Plant & Equipment | 294K | 1.75M | 1.6M | 2.1M | 2.32M | 2.25M |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.96M | 180K | 116K | 234K | 838K | 726K |
| Total Assets | 8.32M▲ 0% | 92.41M▲ 1010.8% | 200.21M▲ 116.6% | 368M▲ 83.8% | 496.77M▲ 35.0% | 806.88M▲ 62.4% |
| Asset Turnover | - | - | - | - | - | - |
| Asset Growth % | - | 1010.84% | 116.65% | 83.81% | 34.99% | 62.42% |
| Total Current Liabilities | 24.88M | 13.42M | 22.58M | 21.44M | 23.32M | 36.64M |
| Accounts Payable | 2.38M | 2.56M | 16.16M | 12.63M | 7.95M | 9.02M |
| Days Payables Outstanding | 2.69K | - | - | - | - | 11.71K |
| Short-Term Debt | 16.69M | 5M | 0 | 0 | 0 | 611K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 1.45M | 3.62M | 5.79M | 7.21M | 27.01M |
| Current Ratio | 0.20x | 6.74x | 8.79x | 17.06x | 21.17x | 21.94x |
| Quick Ratio | 0.20x | 6.74x | 8.79x | 17.06x | 21.17x | 21.94x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5.3M | 143.19M | 1.03M | 1.44M | 29.87M | 30.41M |
| Long-Term Debt | 4.95M | 404K | 0 | 0 | 28.32M | 1.25M |
| Capital Lease Obligations | 0 | 1.33M | 1.03M | 1.44M | 1.55M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 353K | 141.45M | 0 | 0 | 0 | 29.16M |
| Total Liabilities | 30.18M | 156.61M | 23.61M | 22.88M | 53.19M | 67.05M |
| Total Debt | 21.64M | 7.06M | 1.33M | 2.1M | 30M | 1.86M |
| Net Debt | 17.14M | -80.98M | -193.28M | -358.28M | -162.43M | -89.28M |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.07x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -4.98x | -14.33x | - | - | -189.56x | -57.73x |
| Total Equity | -21.86M▲ 0% | -64.2M▼ 193.7% | 176.6M▲ 375.1% | 345.12M▲ 95.4% | 443.59M▲ 28.5% | 739.83M▲ 66.8% |
| Equity Growth % | - | -193.69% | 375.06% | 95.43% | 28.53% | 66.78% |
| Book Value per Share | -14.46 | -80.11 | 169.89 | 15.47 | 16.07 | 20.96 |
| Total Shareholders' Equity | -21.86M | -64.2M | 176.6M | 345.12M | 443.59M | 739.83M |
| Common Stock | 2K | 0 | 2K | 2K | 3K | 4K |
| Retained Earnings | -112.82M | -65.39M | -112.22M | -188.65M | -298M | -510.19M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 289K | 965K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
IRON Cash Flow Statement
Disc Medicine, Inc. (IRON) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
| Cash from Operations | -32.71M | -27.53M | -42.25M | -73.46M | -93.93M | -180.39M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | 15.82% | -53.45% | -73.87% | -27.86% | -92.06% |
| Net Income | -40.84M | -35.97M | -46.83M | -76.43M | -109.36M | -212.18M |
| Depreciation & Amortization | 322K | 32K | 89K | 100K | 156K | 281K |
| Stock-Based Compensation | 983K | 507K | 2.09M | 5.53M | 16.82M | 34.34M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 6.49M | 6.61M | 272K | 290K | -4.77M | -6.36M |
| Working Capital Changes | 337K | 1.29M | 2.13M | -2.95M | 3.23M | 3.53M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -2.41M | 1.31M | 526K | -3.74M | -4.68M | 1.07M |
| Cash from Investing | -22K | -68K | -151K | -89K | -292.33M | -394.3M |
| Capital Expenditures | -22K | -68K | -151K | -89K | -505K | -933K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 34.25M | 89.93M | 148.98M | 239.38M | 218.31M | 473.41M |
| Debt Issued (Net) | 14M | -4.58M | 0 | 0 | 28.99M | 0 |
| Equity Issued (Net) | 20.08M | 89.86M | 53.5M | 199.08M | 187.3M | 472.83M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 163K | 4.65M | 95.48M | 40.3M | 2.02M | 578K |
| Net Change in Cash | 1.52M▲ 0% | 62.33M▲ 4008.6% | 106.58M▲ 71.0% | 165.83M▲ 55.6% | -167.94M▼ 201.3% | -101.28M▲ 39.7% |
| Free Cash Flow | -32.73M▲ 0% | -27.6M▲ 15.7% | -42.4M▼ 53.6% | -73.55M▼ 73.5% | -94.43M▼ 28.4% | -181.33M▼ 92.0% |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | 15.67% | -53.62% | -73.46% | -28.39% | -92.02% |
| FCF per Share | -21.65 | -34.44 | -40.79 | -3.30 | -3.42 | -5.14 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.77x | 0.90x | 0.96x | 0.86x | 0.85x |
| Interest Paid | 345K | 307K | 0 | 0 | 198K | 0 |
| Taxes Paid | 0 | 0 | 0 | 112K | 299K | 0 |
IRON Key Ratios
Disc Medicine, Inc. (IRON) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -83.32% | -29.3% | -27.73% | -35.86% |
| Return on Invested Capital (ROIC) | - | - | - | - | -72.61% | -38% |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.07x | 0.00x |
| Interest Coverage | -4.98x | -14.33x | - | - | -189.56x | -57.73x |
| FCF Conversion | 0.80x | 0.77x | 0.90x | 0.96x | 0.86x | 0.85x |
IRON SEC Filings & Documents
Disc Medicine, Inc. (IRON) SEC filings — annual & quarterly reports (10-K, 10-Q)
IRON Frequently Asked Questions
Disc Medicine, Inc. (IRON) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Disc Medicine, Inc. (IRON) grew revenue by 0.0% over the past year. Growth has been modest.
Disc Medicine, Inc. (IRON) reported a net loss of $212.2M for fiscal year 2025.
Dividend & Returns
Disc Medicine, Inc. (IRON) has a return on equity (ROE) of -35.9%. Negative ROE indicates the company is unprofitable.
Disc Medicine, Inc. (IRON) had negative free cash flow of $181.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More IRON
Disc Medicine, Inc. (IRON) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates